Physiologically based approaches towards the prediction of pharmacokinetics: In vitro-in vivo extrapolation

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 6, 2007, Pages 865-878

  De Buck, Stefan S ^a   Mackie, Claire E ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

In vitro in vivo extrapolation; Physiologically based pharmacokinetics; Prediction modelling and simulation

Indexed keywords

DRUG; DRUG METABOLIZING ENZYME;

COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; FIRST PASS EFFECT; HUMAN; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; REVIEW; TISSUE DISTRIBUTION;

ALGORITHMS; ANIMALS; DRUG INDUSTRY; HUMANS; METABOLIC CLEARANCE RATE; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 37349017573     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.6.865     Document Type: Review

References (111)

1. THEIL FP, GUENTERT TW, HADDAD S, POULIN P: Utility of physiologically based pharmacokinetic models to drug development and rational dnag discovery candidate selection. Toxicol. Lett. (2003) 138(1-2):29-49.
2. VAN DE WATERBEEMD H, GIFFORD E: ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. (2003) 2(3):192-204.
3. DREWS J: Jurgen Drews discusses the future of the industry. Interviewed by Rebecca N Lawrence. Drug Discov. Today (2001) 6(7):338-341.
4. DREWS J: Stategic trends in the drug industry. Drug Discov. Today (2003) 8(9):411-420.
5. PANG KS, ROWLAND M: Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. (1977) 5(6):625-653.
6. ROBERTS MS, ROWLAND M: A dispersion model of hepatic elimination. 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. (1986) 14(3):227-260.
7. WILKINSON GR, SHAND DG: Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. (1975) 18(4):377-390.
8. IWATSUBO T, HIROTA N, OOIE T et al.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. (1997) 73(2):147-171.
9. MIYAUCHI S, SUGIYAMA Y, SATO H, SAWADA Y, IGA T, HANANO M: Effect of a diffusional barrier to a metabolite across hepatocytes on its kinetics in "enzyme-distributed" models: a computer-aided simulation study. J. Pharmacokinet. Biopharm. (1987) 15(4):399-421.
10. MIYAUCHI S, SUGIYAMA Y, SAVADA Y, MORITA K, IGA T, HANANO M: Kinetics of hepatic transport of 4-methylumbelliferone in rats. Analysis by multiple indicator dilution method. J. Pharmacokinet. Biopharm. (1987) 15(1):25-38.
11. SATO H, SUGIYAMA Y, MIYAUCHI S, SAVADA Y, IGA T, HANANO M: A simulation study on the effect of a uniform diffusional barrier across hepatocytes on drug metabolism by evenly or unevenly distributed uni-enzyme in the liver. J. Pharm. Sci. (1986) 75(1):3-8.
12. ITO K, HOUSTON JB: Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res. (2004) 21(5):785-792.
13. GUMUCIO JJ, MILLER DL. Functional implications of liver cell heterogeneity. Gastroenterology (1981) 80(2):393-403.
14. BASS L, KEIDING S: Physiologically based models and strategic experiments in hepatic pharmacology. Biochem. Pharmacol. (1988) 37(8):1425-1431.
15. ITO K, HOUSTON JB: Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res. (2005) 22(1):103-112.
16. IWATSUBO T, HIROTA N, OOIE T, SUZUKI H, SUGIYAMA Y: Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos. (1996) 17(4):273-310.
17. HOUSTON JB: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. (1994) 47(9):1469-1479.
18. OBACH RS: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. (1999) 27(11):1350-1359.
19. OBACH RS, BAXTER JG, LISTON TE et al.: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. (1997) 283(1):46-58.
20. JONES HM, HOUSTON JB: Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos. (2004) 32(9):973-982.
21. HOUSTON JB, KENWORTHY KE: In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. (2000) 28(3):246-254.
22. BARTER ZE, BAYLISS MK, BEAUNE PH et al.: Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. (2007) 8(1):33-45.
23. PELKONEN O, TURPEINEN M, UUSITALO J, RAUTIO A, RAUNIO H: Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin. Pharmacol. Toxicol. (2005) 96(3):167-175.
24. BROWN HS, GRIFFIN M, HOUSTON JB: Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab. Dispos. (2007) 35(2):293-301.
25. LAVE T, DUPIN S, SCHMITT C et al.: The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm. Res. (1997) 14(2):152-155.
26. MINERS JO, KNIGHTS KM, HOUSTON JB, MACKENZIE PI: In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol. (2006) 71(11):1531-1539.
27. BLANCHARD N, HEWITT NJ, SILBER P, JONES H, COASSOLO P, LAVE T: Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations. J. Pharm. Pharmacol. (2006) 58(5):633-641.
28. LECLUYSE EL: Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. (2001) 13(4):343-368.
29. JOUIN D, BLANCHARD N, ALEXANDRE E et al.: Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. Eur. J. Pharm. Biopharm. (2006) 63(3):347-355.
30. PROCTOR NJ, TUCKER GT, ROSTAMI-HODJEGAN A: Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica (2004) 34(2):151-178.
31. GUILLOUZO A, CORLU A, ANINAT C, GLAISE D, MOREL F, GUGUEN-GUILLOUZO C: The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. (2007) 168(1):66-73.
32. GALETIN A, BROWN C, HALLIFAX D, ITO K, HOUSTON JB: Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab. Dispos. (2004) 32(12):1411-1420.
33. RAWDEN HC, CARLILE DJ, TINDALL A et al.: Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica (2005) 35(6):603-625.
34. ROSTAMI-HODJEGAN A, TUCKER GT: Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. (2007) 6(2):140-148.
35. BROWN HS, ITO K, GALETIN A, HOUSTON JB: Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol. (2005) 60(5):508-518.
36. GALETIN A, BURT H, GIBBONS L, HOUSTON JB: Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab. Dispos. (2006) 34(1):166-175.
37. HOUSTON JB, GALETIN A: Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab. Rev. (2003) 35(4):393-415.
38. HOUSTON JB, CARLILE DJ: Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab. Rev. (1997) 29(4):891-922.
39. HAKOOZ N, ITO K, RAWDEN H et al.: Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm. Res. (2006) 23(3):533-539.
40. LIU L, PANG KS: The roles of transporters and enzymes in hepatic drug processing. Drug Metab. Dispos. (2005) 33(1):1-9.
41. KALVASS JC, TESS DA, GIRAGOSSIAN C, LINHARES MC, MAURER TS: Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab. Dispos. (2001) 29(10):1332-1336.
42. OBACH RS: Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab. Dispos. (1997) 25(12):1359-1369.
43. RILEY RJ, MCGINNITY DF, AUSTIN RP: A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. (2005) 33(9):1304-1311.
44. DE BUCK SS, SINHA VK, FENU LA, GILISSEN RA, MACKIE CE, NIJSEN MJ: The prediction of drug metabolism, tissue distribution and bioavailability of 50 structurally diverse compounds in rat using mechanism-based ADME prediction tools. Drug Metab. Dispos. (2007) 35(4):649-659.
45. DE BUCK SS, SINHA VK, FENU LA, NIJSEN MJ, MACKIE CE, GILISSEN RA: Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos. (2007) 35(10):1766-1780.
46. VENKATAKRISHNAN K, VON MOLTKE LL, OBACH RS, GREENBLATT DJ: Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J. Pharmacol. Exp. Ther. (2000) 293(2):343-350.
47. NARITOMI Y, TERASHITA S, KIMURA S, SUZUKI A, KAGAYAMA A, SUGIYAMA Y: Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos (2001) 29(10):1316-1324.
48. LAVE T, COASSOLO P, REIGNER B: Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin. Pharmacokinet. (1999) 36(3):211-231.
49. SHIRAN MR, PROCTOR NJ, HOWGATE EM, ROWLAND-YEO K, TUCKER GT, ROSTAMI-HODJEGAN A: Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica (2006) 36(7):567-580.
50. ZUEGGE J, SCHNEIDER G, COASSOLO P, LAVE T: Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin. Pharmacokinet. (2001) 40(7):553-563.
51. LECLUYSE EL, FIX JA, AUDUS KL, HOCHMAN JH: Regeneration and maintenance of bile canalicular networks in collagen-sandwiched hepatocytes. Toxicol. In Vitro (2000) 14(2):117-132.
52. LIU X, CHISM JP, LECLUYSE EL, BROUWER KR, BROUWER KL: Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab. Dispos. (1999) 27(6):637-644.
53. MAHMOOD I: Interspecies scaling of renally secreted drugs. Life Sci. (1998) 63(26):2365-2371.
54. MAHMOOD I, SAHAJWALLA C: Interspecies scaling of biliary excreted drugs. J. Pharm. Sci. (2002) 91(8):1908-1914.
55. MORDENTI J: Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci. (1986) 75(11):1028-1040.
56. SAWADA Y, HANANO M, SUGIYAMA Y, HARASHIMA H, IGA T: Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J. Pharmacokinet. Biopharm. (1984) 12(6):587-596.
57. IGARI Y, SUGIYAMA Y, SAWADA Y, IGA T, HANANO M: Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model. J Pharmacokinet. Biopharm. (1983) 11(6):577-593.
58. SAWADA Y, HANANO M, SUGIYAMA Y, IGA T: Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J. Pharmacokinet. Biopharm. (1985) 13(5):477-492.
59. POULIN P, THEIL FP: A priori prediction of tissue-plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. (2000) 89(1):16-35.
60. POULIN P, THEIL FP: Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. (2002) 91(1):129-156.
61. BJORKMAN S: Prediction of the volume of distribution of a drug: which tissue-plasma partition coefficients are needed? J. Pharm. Pharmacol. (2002) 54(9):1237-1245.
62. RICHTER WF, STARKE V, WHITBY B: The distribution pattern of radioactivity across different tissues in quantitative whole-body autoradiography (QWBA) studies. Eur. J. Pharm. Sci. (2006) 28(1-2):155-165.
63. CLAUSEN J, BICKEL MH: Prediction of drug distribution in distribution dialysis and in vivo from binding to tissues and blood. J. Pharm. Sci. (1993) 82(4):345-349.
64. LIN JH, SUGIYAMA Y, AWAZU S, HANANO M: In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. J. Pharmacokinet. Biopharm. (1982) 10(6):637-647.
65. SCHUHMANN G, FICHTL B, KURZ H: Prediction of drug distribution in vivo on the basis of in vitro binding data. Biopharm. Drug Dispos. (1987) 8(1):73-86.
66. REINOSO RF, TELFER BA, ROWLAND M: In vitro studies of teicoplanin binding to rat tissues and erythrocytes. Eur. J. Pharm. Sci. (1998) 6(2):145-152.
67. LOMBARDO F, OBACH RS, SHALAEVA MY, GAO F: Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. J. Med. Chem. (2004) 47(5):1242-1250.
68. LOMBARDO F, OBACH RS, SHALAEVA MY, GAO F: Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem. (2002) 45(13):2867-2876.
69. HADDAD S, POULIN P, KRISHNAN K: Relative lipid content as the sole mechanistic determinant of the adipose tissue:blood partition coefficients of highly lipophilic organic chemicals. Chemosphere (2000) 40(8):839-843.
70. PAYNE MP, KENNY LC: Comparison of models for the estimation of biological partition coefficients. J. Toxicol. Environ. Health A (2002) 65(13):897-931.
71. POULIN P, KRISHNAN K: A tissue composition-based algorithm for predicting tissue:air partition coefficients of organic chemicals. Toxicol. Appl. Pharmacol. (1996) 136(1):126-130.
72. POULIN P, SCHOENLEIN K, THEIL FP: Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J. Pharm. Sci. (2001) 90(4):436-447.
73. ELLMERER M, SCHAUPP L, BRUNNER GA et al.: Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am. J. Physiol. Endocrinol. Metab. (2000) 278(2):E352-E356.
74. JONES HM, PARROTT N, JORGA K, LAVE T: A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. (2006) 45(5):511-542.
75. PARROTT N, JONES H, PAQUEREAU N, LAVE T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin. Pharmacol. Toxicol. (2005) 96(3):193-199.
76. PARROTT N, PAQUEREAU N, COASSOLO P, LAVE T: An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J. Pharm. Sci. (2005) 94(10):2327-2343.
77. RODGERS T, LEAHY D, ROWLAND M: Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. (2005) 94(6):1259-1276.
78. RODGERS T, LEAHY D, ROWLAND M: Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst β-blocking drugs in rat. J. Pharm. Sci. (2005) 94(6):1237-1248.
79. RODGERS T, ROWLAND M: Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. (2006) 95(6):1238-1257.
80. YOKOGAWA K, ISHIZAKI J, OHKUMA S, MIYAMOTO K: Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a Physiologically based pharmacokinetic model. Methods Find. Exp. Clin. Pharmacol. (2002) 24(2):81-93.
81. MACHERAS P, ARGYRAKIS P: Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Pharm. Res. (1997) 14(7):842-847.
82. AGORAM B, WOLTOSZ WS, BOLGER MB: Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. (2001) 50(Suppl. 1):S41-S67.
83. CAMENISCH G, FOLKERS G, VAN DE WATERBEEMD H: Review of theoretical passive drug absorption models: historical background, recent developments and limitations. Pharm. Acta Helv. (1996) 71(5):309-327.
84. SIETSEMA WK: The absolute oral bioavailability of selected drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. (1989) 27(4):179-211.
85. GRASS GM, SINKO PJ: Physiologically-based pharmacokinetic simulation modelling. Adv. Drug Deliv. Rev. (2002) 54(3):433-451.
86. LIN JH: Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. (1995) 23(10):1008-1021.
87. LENNERNAS H: Human intestinal permeability. J. Pharm. Sci. (1998) 87(4):403-410.
88. YU LX, AMIDON GL: A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. (1999) 186(2):119-125.
89. WILLMANN S, SCHMITT W, KELDENICH J, DRESSMAN JB: A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm. Res. (2003) 20(11):1766-1771.
90. WILLMANN S, SCHMITT W, KELDENICH J, LIPPERT J, DRESSMAN JB: A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. (2004) 47(16):4022-4031.
91. WILLMANN S, LIPPERT J, SCHMITT W: From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin. Drug Metab. Toxicol. (2005) 1(1):159-168.
92. PARROTT N, LAVE T: Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur. J. Pharm. Sci. (2002) 17(1-2):51-61.
93. WENLOCK MC, AUMN RP, BARTON P, DAVIS AM, LEESON PD: A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. (2003) 46(7):1250-1256.
94. JONES HM, PARROTT N, OHLENBUSCH G, LAVE T: Predicting pharmacokinctic food effects using biorelevant solubility media and physiologically based modelling. Clin. Pharmacokinet. (2006) 45(12):1213-1226.
95. NICOLAIDES E, SYMILLIDES M, DRESSMAN JB, REPPAS C: Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. (2001) 18(3):380-388.
96. GERLOWSKI LE, JAIN RK: Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. (1983) 72(10):1103-1127.
97. NESTOROV I: Whole body pharmacokinetic models. Clin. Pharmacokinet. (2003) 42(10):883-908.
98. NESTOROV IA, AARONS LJ, ARUNDEL PA, ROWLAND M: Lumping of whole-body physiologically based pharmacokinetic models. J. Pharmacokinet. Biopharm. (1998) 26(1):21-46.
99. NESTOROV I: Whole-body physiologically based pharmacokinetic models. Expert Opin. Drug Metab. Toxicol. (2007) 3(2):235-249.
100. LEUNG HW: Development and utilization of physiologically based pharmacokinetic models for toxicological applications. J. Toxicol. Environ. Health (1991) 32(3):247-267.
101. EDGINTON AN, SCHMITT W, VOITH B, WILLMANN S: A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet. (2006) 45(7):683-704.
102. EDGINTON AN, SCHMITT W, WILLMANN S: Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. (2006) 45(10):1013-1034.
103. JOHNSON TN, ROSTAMI-HODJEGAN A, TUCKER GT: Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. (2006) 45(9):931-956.
104. ROWLAND M, BALANT I, PECK C: Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, 29-30 May 2002). AAPS Pharm. Sci. (2004) 6(1):E6.
105. BOXENBAUM H: Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev. (1984) 15(5-6):1071-1121.
106. BOXENBAUM H: Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. (1982) 10(2):201-227.
107. BOXENBAUM H, RONFELD R: Interspecies pharmacokinetic scaling and the Dedrick plots. Am. J. Physiol. (1983) 245(6):R768-R775.
108. WEISS M, SZIEGOLEIT W, FORSTER W: Dependence of pharmacokinetic parameters on the body weight. Int. J. Clin. Pharmacol. Biopharm. (1977) 15(12):572-575.
109. BRODIE BB: Of mice, microsomes, and men. Pharmacologist (1964) 6:12-26.
110. LAVE T, DUPIN S, SCHMITT C, CHOU RC, JAECK D, COASSOLO P: Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J. Pharm. Sci. (1997) 86(5):584-590.
111. MAHMOOD I, BALIAN JD: Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J. Pharm. Sci. (1996) 85(4):411-414.